DraftColorado Rocky Mountain Health PlansPolicy CS016OH.C

Chelation Therapy (for Ohio Only)

This policy governs medical necessity and coverage of chelation therapy for members in the state of Ohio, specifying covered indications (heavy metal overload/toxicity) and non-covered/unproven uses.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyChelation Therapy (for Ohio Only)

Policy CodePolicy CS016OH.C

Change TypeEditorial revision + evidence update

Effective DateAug 1, 2025

Next Review Date

Key ActionObtain and document validated diagnostic testing demonstrating metal intoxication to support authorization for chelation therapy.

SourceLink

POLICY UPDATE CHANGES

Replaced language indicating 'chelation for heavy metal toxicity and overload conditions (e.g., iron, copper, lead, aluminum) is proven and medically necessary and not addressed in this policy' with 'chelation for heavy metal toxicity and overload conditions (e.g., iron, copper, lead, aluminum) is proven and medically necessary'.

Updated Clinical Evidence and References sections to reflect the most current information.

Title change from 'Chelation Therapy for Non-Overload Conditions (for Ohio Only)' to current title.

Ohio-onlyjurisdiction

S9355 + J-codescodes referenced

Non-overloadexplicit exclusions

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

possible subgroup signal

CS016OH.Barchived version

Coverage Criteria for Chelation Therapy

Medically necessary: Heavy metal overload/toxicity

Covered when ALL of the following are met

Heavy metal overload/toxicity indication: Documented heavy metal toxicity or overload (e.g., iron, copper, lead, aluminum) with appropriate diagnostic workup and reference values.clinical diagnosis based on validated testing in appropriate biological samples

Chelation therapy is an established treatment for removing metal toxins and demonstrated effective in iron-overload states (thalassemia, transfusion-dependent anemias, select MDS) per randomized trials and systematic reviews.

Evidence-supported indications and populations

Evidence-supported clinical scenarios: Use of chelation in transfusion-dependent anemias (thalassemia, sickle cell disease), iron-overload in myelodysplastic syndromes (low- to intermediate-risk MDS), and randomized comparisons of chelators (deferoxamine, deferiprone, deferasirox) including combination regimens are supported by RCTs and systematic reviews summarized in the policy.

Studies report improvements in serum ferritin, liver iron concentration, cardiac MRI indices, and event-free survival in select populations.

Indications consistent with guideline-supported use

Covered when ALL of the following are met

Documented metal intoxication: Validated diagnostic testing in appropriate biological samples documents metal intoxication (e.g., lead, iron overload) and the indication aligns with FDA-approved uses or accepted toxicology practice.diagnosis confirmed by validated tests

Professional societies (AAFP, ACMT) state chelation is appropriate only for documented metal intoxication.

Not medically necessary / investigational indications

Not supported / investigational when ANY of the following apply

Alzheimer's disease: Use of metal‐protein attenuating compounds (MPACs) or chelation for Alzheimer disease has not demonstrated consistent cognitive benefit in trials; evidence insufficient to support routine use.

Cochrane review and small trials show no consistent cognitive improvement.

Autism spectrum disorder: Pharmaceutical chelation (e.g., DMSA) has not shown benefit for core ASD symptoms and has been associated with serious adverse events; thus chelation for ASD is not supported.

Cochrane review and trial data indicate lack of efficacy and potential harms.

Cardiovascular disease (general): EDTA-based chelation therapy did not reduce major cardiovascular events in recent placebo-controlled trials overall; systematic reviews find insufficient evidence to support routine use for ASCVD despite exploratory subgroup signals.

TACT/TACT2 and Cochrane reviews show mixed or null primary results; subgroup findings (e.g., diabetes/anterior MI) are hypothesis-generating only.

Medically necessary coverage conditions

Covered when ALL of the following are met

FDA-approved indication: Use of chelating agents is for FDA-approved indications (metal poisoning, iron overload) as referenced in a recognized drug compendium.

Coverage for chelating agents is limited to FDA‑approved uses per drug compendia guidance.

Consistency with state/contractual rules: Coverage and prior authorization decisions conform to federal, state (Ohio Administrative Code), and contractual requirements where applicable.

Refer to Ohio OAC and benefit contract for governing rules.

Not supported indications per guidelines

Non-overload indications lacking support: Chelation therapy for cardiovascular disease (including attempting to improve angina or exercise tolerance), stable ischemic heart disease, autism, and other non‑overload indications is not recommended by major guideline bodies and therefore not supported by this policy for those indications.

AHA and other guideline statements indicate EDTA is not FDA-approved for preventing or treating CVD and recommend against chelation for these uses.

Chelation therapy is not supported for chronic, progressive non-overload conditions. High-quality, peer‑reviewed studies do not demonstrate that chelation improves clinical outcomes in diseases where heavy metal toxicity has not been documented, and many investigations suffer from small sample sizes, heterogenous populations, nonstandard regimens, and insufficient follow-up. Examples of these non-overload chronic diseases include cardiovascular disease, rheumatoid arthritis, cancer, diabetes, Alzheimer’s disease, autism spectrum disorder, and Parkinson’s disease.

Chelation for indications other than documented metal intoxication or iron overload is considered investigational or not medically necessary. Guideline and toxicology organizations state chelation should be reserved for cases with validated diagnostic testing in appropriate biological samples. In particular, chelation has not been shown to be effective for treating alleged mercury 'toxicity' from dental amalgam fillings, and routine chelation for such dental‑amalgam concerns is not supported.

Use of chelation agents for non‑FDA‑approved indications is excluded from coverage unless the use falls within an agent’s approved labeling for metal poisoning or iron overload. Major guideline bodies (AHA, ACP/ACC, Canadian Cardiovascular Society, NICE, and others) recommend against chelation for conditions such as attempting to improve angina or exercise tolerance in stable ischemic heart disease, treating autism, or managing neurodegenerative disorders. These guideline statements, together with compendium and regulatory references, support limiting coverage to recognized, approved indications.

Summary: Chelation therapy for non‑overload conditions, including autism spectrum disorder (ASD), is not supported by current high‑quality evidence and is considered not medically necessary. Reported risks, including serious adverse events in some trials, and lack of demonstrated clinical benefit underpin this position.

Professional society guidance states that the use of chelation to improve symptoms or reduce cardiovascular risk in individuals with stable ischemic heart disease is not recommended. Clinical practice guidelines from the American College of Physicians and joint cardiovascular societies explicitly advise against using chelation for symptom relief or risk reduction in stable IHD.

The use of EDTA (edetate disodium) or other chelation regimens for the prevention or treatment of cardiovascular disease, or to improve angina or exercise tolerance in stable ischemic heart disease, is not supported. The 2023 AHA guideline notes EDTA is not FDA‑approved for preventing or treating CVD, and international guideline groups recommend against these uses.

Regimens and Specific Agents

Regimen / Indication	Summary of Evidence	Coverage Stance
Dexrazoxane — cardioprotection during anthracycline therapy in breast cancer	Strongest evidence among chelators for reducing anthracycline-related cardiotoxicity in women receiving anthracyclines for breast cancer; identified by Hayes health technology assessment updates and policy review as the most consistent benefit, but additional studies with longer follow-up are needed to confirm effects on survival.	Covered

Coding and Billing

Referenced J- and miscellaneous codesHCPCS

J0470	Injection, dimercaprol, per 100 mg.
J0600	Injection, edetate calcium disodium, up to 1,000 mg.
J0895	Injection, deferoxamine mesylate, 500 mg.
J3490	Unclassified drugs.
J3520	Edetate disodium, per 150 mg.
J8499	Prescription drug, oral, nonchemotherapeutic, NOS.
M0300	IV chelation therapy (chemical endarterectomy)

Home infusion HCPCSHCPCS

S9355

Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem

Covered CPT Codes (none specified in this section)mixed

No codes listed

No explicit codes listed in this document fragmentmixed

No codes listed

Clinical thresholds and outcomes referenced

Serum ferritinReferenced as a primary biomarker reduced by iron chelation; multiple studies report significant correlations between chelator adherence and lower serum ferritin

Liver iron concentration (LIC)LIC measured by R2*/MRI used as primary outcome (e.g., noninferiority trial assessing change in LIC at 12 months)

Cardiac MRI T2*/R2* valuesCardiac T2* (and R2*) MRI indices cited as endpoints for cardiac iron assessment and noninferiority comparisons between agents

Event-free survival (EFS)EFS used as the primary endpoint in TELESTO (MDS trial) with reported prolongation of median EFS with deferasirox vs placebo

Blood lead levels (for EDTA trials)TACT/EDTA trial reported reduction in median blood lead from baseline to infusion 40 (e.g., 9.03 μg/L to 3.46 μg/L; p < .001)

Provider Actions, Prior Authorization & Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for chelation-related HCPCS/J-codes when applicable under the member's benefit plan and state or federal contract. Providers should obtain PA before initiating treatment when billing the listed codes.

Affected codes include J0470, J0600, J0895, J3490, J3520, J8499, M0300, S9355

Denial Risk

PA & Denial Risk for Non‑Indicated Uses

Prior authorization is recommended and will be scrutinized when chelation is requested for conditions other than documented metal intoxication or iron overload (for example, chronic non-overload diseases or dental amalgam "toxicity"). Such requests frequently do not meet coverage criteria and are at high risk for denial.

Requests for chelation for chronic, progressive non-overload diseases (e.g., CVD, Alzheimer's, autism) are commonly denied
Requests citing dental amalgam 'toxicity' are routinely considered not medically necessary

Definitions

Heavy metal overload / toxicity

DefinitionClinical condition characterized by accumulation of metals (e.g., iron, copper, lead, aluminum, mercury) established by diagnostic evaluation and warranting chelation therapy

ExamplesIron overload (thalassemia, transfusion-dependent anemias, MDS), lead poisoning, copper toxicity

Diagnostic requirementRequires validated testing and appropriate biological samples with reference values to document intoxication

Non-overload condition

DefinitionConditions in which acute or chronic heavy metal toxicity has not been demonstrated and chelation is hypothesized to provide benefit but lacks robust evidence

ExamplesCardiovascular disease, rheumatoid arthritis, cancer, diabetes, Alzheimer’s disease, autism spectrum disorder, Parkinson’s disease

Background and Evidence Summary

Background: Chelation therapy is an established, evidence‑based treatment for the removal of specific metal toxins in clinically confirmed heavy metal overload or toxicity states (for example, iron, copper, lead, and aluminum). Appropriate use requires a documented diagnosis supported by validated testing, and selection of the chelating agent, dose, and route should align with the clinical indication and accepted toxicology practice.

Revision History and Policy Changes

2025-08-01RevisionLatest

Policy title updated (previously 'Chelation Therapy for Non-Overload Conditions (for Ohio Only)'); Coverage Rationale wording revised to state that chelation for heavy metal toxicity and overload conditions is proven and medically necessary; Clinical Evidence and References sections updated; prior policy version CS016OH.B archived.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyChelation Therapy (for Ohio Only)

Policy CodePolicy CS016OH.C

Change TypeEditorial revision + evidence update

Effective DateAug 1, 2025

Next Review Date

Key ActionObtain and document validated diagnostic testing demonstrating metal intoxication to support authorization for chelation therapy.

SourceLink

On This Page

Parkinson's disease: Small RCTs of iron chelator deferiprone showed regional brain iron reductions but no conclusive symptomatic benefit; evidence insufficient for routine clinical use.

Small sample sizes and non-significant clinical endpoints.

Infusion regimen (key protocol detail)

EDTA infusion regimen (TACT)40 weekly infusions of an EDTA-based chelation solution (administered in the multicenter, placebo-controlled trial)

Co-interventions in trialConcurrent twice-daily high-dose multivitamin and mineral supplements were randomized in the TACT protocol alongside infusion/placebo

Population criteria for regimen trialsParticipants were prior MI patients with diabetes, aged ≥50 years and ≥6 weeks post-MI in the 40-infusion trial

Follow-up duration (TACT trial)

Median follow-up (TACT)Median follow-up reported as 48 months in the EDTA-based chelation trial

Planned maximum follow-upFollow-up was planned for up to 60 months in the trial protocol

Primary endpoint observation windowPrimary event cumulative incidence reported at 5 years (5-year cumulative incidence provided)

Miscellaneous coding placeholder

Coding placeholderNo specific threshold or code provided in this fragment; refer to the policy coding section for applicable HCPCS/J-codes

ActionWhen submitting claims, reference federal/state/contractual requirements (OAC) and applicable payer coding guidance

Documentation noteBill drugs and nursing visits separately per home infusion guidance (see HCPCS S9355 description)

Note

Coverage Limited to FDA‑Approved Indications

Coverage is limited to FDA‑approved indications for each chelating agent (metal poisoning, iron overload) as referenced in a recognized drug compendium. Uses outside these indications are generally not covered.

Coverage limited to FDA‑approved indications per drug compendia (e.g., AHFS, DrugDex)
FDA: chelating agents approved when used for metal poisoning or iron overload

Documentation Required

Document the Diagnosis of Heavy Metal Overload/Intoxication

Providers must document the diagnosis of heavy metal overload or toxicity with an appropriate diagnostic workup prior to authorization and treatment. Documentation should include clinical history, exposure assessment, and use of validated testing methods with appropriate biological specimens and reference values.

Document history of exposure and clinical signs/symptoms
Specify which biological samples and validated tests were used (e.g., blood, urine, tissue) and reference laboratory norms

Documentation Required

Documentation Required for Chelation in Metal Intoxication

For chelation in documented metal intoxication, include objective diagnostic evidence from validated testing of appropriate biological samples (blood, urine, tissue) and baseline organ function testing. Provide results, dates, laboratory reference ranges, and rationale for chelation agent selection.

Attach specific test results (lead, iron, copper, mercury, etc.) with dates and lab reference ranges
Include baseline renal and hepatic function tests and any prior treatments attempted

Documentation Required

Documentation and Regulatory References

When determining coverage, reference applicable federal, state, and contractual requirements and use InterQual or other approved utilization management criteria as available. Cite relevant professional society guidance (ACMT, AAFP, ACP/AHA) when documenting medical necessity.

Follow InterQual® criteria for medical necessity when available
In the event of conflicts, federal, state (e.g., OAC) or contractual requirements govern coverage decisions

Step Therapy

Step Therapy: Use Standard Care First

Use standard evidence‑based therapies before initiating chelation for conditions where chelation is not first‑line. For stable ischemic heart disease and other guideline‑directed conditions, do not substitute chelation for recommended therapies; step therapy requires trial of standard care prior to chelation.

Do not use chelation to replace guideline-recommended therapies for stable ischemic heart disease
Document prior trials of recommended standard treatments when chelation is requested for cardiovascular indications

Policy stanceChelation for non-overload conditions is considered investigational or not medically necessary due to insufficient evidence

EDTA (edetate disodium)

Agent definitionEDTA (edetate disodium) is an IV chelating agent studied in multi-week infusion regimens for removal of divalent metals such as lead and used in cardiovascular trials like TACT/TACT2

Regimen contextStudied as 40 weekly infusions in a multicenter, placebo-controlled trial for post-MI patients with diabetes

Safety considerationsAHA notes EDTA is not FDA-approved for preventing or treating CVD; chelators may cause hypocalcemia, kidney injury, and other adverse effects

Iron chelators (deferasirox, deferiprone / DFP, deferoxamine)

Agent classOral iron chelators (deferasirox, deferiprone/DFP, and injectable deferoxamine/DFO) used to reduce iron burden in iron-overload states

IndicationsUsed in transfusion-dependent anemias (thalassemia, SCD), iron-overload in MDS, and other iron-overload conditions with evidence from RCTs and systematic reviews

Key outcomesDemonstrated effects include reductions in serum ferritin and LIC, changes in cardiac MRI iron indices, and improved event-free or overall survival in select studies

Use of chelating agents for metal poisoning or iron overload (FDA-approved indications)

FDA-approved usesChelating agents are FDA-approved when used for metal poisoning or iron overload treatment as referenced in recognized drug compendia

Coverage implicationUse is limited to FDA-approved indications per compendia (e.g., AHFS, DrugDex) and should be documented when seeking coverage

Reference guidancePolicy notes FDA status is informational and not sole basis for coverage; compendia references and state/contractual rules govern coverage determinations

Administration of chelation for non-overload indications (guideline-advised against)

Guideline recommendationsMajor guideline bodies advise against or do not recommend chelation for non-overload indications such as CVD, autism, and other chronic diseases

Examples of discouraged usesAttempts to improve angina/exercise tolerance in stable ischemic heart disease, treating autism core symptoms, or routine CVD prevention

Safety and evidence concernsGuidelines and toxicology groups cite insufficient evidence of benefit and potential for significant adverse events with inappropriate chelation